Skip to content

Tag Archives: time

It Can’t Hurt to Ask; A Patient-Centered Quality of Service Assessment of Health Canada’s Medical Cannabis Policy and Program

Background: In 2001 Health Canada responded to a series of Ontario court decisions by creating the Marihuana Medical Access Division (MMAD) and the Marihuana Medical Access Regulations (MMAR). Although Health Canada has conducted a small number of stakeholder consultations, the federal government has never polled federally authorized cannabis patients

POLLACK: Why the Curtain Should Not Have Fallen on RJR’s Premier : Was Product’s Fair Chance Obscured by Smoke and Mirrors?

According to the Centers for Disease Control and Prevention, there have been more than 10 million smoking-related deaths since 1988. I often wonder whether that figure would be lower if it weren’t for the rigidity of the anti-smoking lobby. Our story this week about marketers being unable to tout the potential health benefits of electronic cigarettes brought to mind an Ad Age storyline from 1988: The rise and fall of Premier

Self-governance, control and loss of control amongst drink-drivers

This paper analyses driving under the influence of alcohol and drugs (DUI) from a governmentality perspective. The paper is based on qualitative interviews with 25 persons, convicted of drink-driving and at the time of the interviews participating in Alcohol/Traffic courses in Denmark (mandatory courses for DUI-convicted people)

Determining the Primary Endpoint for a Stimulant Abuse Trial: Lessons Learned from STRIDE (CTN 0037).

Conclusion: We concluded that the best current choice for a primary endpoint is percent days abstinent, as measured by the Time Line Follow Back interview conducted three times a week with recall aided by a take-home Substance Use Diary. To improve the accuracy of the self-reported drug use, the results of qualitative urine drug screens will be used in conjunction with the Time Line Follow Back results. Scientific Significance: There is a need for a standardized endpoint in this field to allow for comparison across treatment studies, and we suggest that the recommended candidate endpoint be considered

Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support

Abstract Aims:  To examine the cost-effectiveness of personal smoking cessation support in Vietnam. Design, setting and participants:  We followed up the population aged 15 and over in 2006 to model the costs and health gains associated with five interventions: physician brief advice; nicotine replacement therapy (patch and gum); Bupropion; and Varenicline.

Examining the Predictive Validity of Low-Risk Gambling Limits with Longitudinal Data

Abstract Aims.  To assess the impact of gambling above the low-risk gambling limits developed by Currie et al.

Effect of prison-based opioid substitution treatment, and post-release retention in treatment, on risk of re-incarceration

Abstract Aims:  People who use heroin are frequently incarcerated multiple times. Reducing re-incarceration of this group is important for reducing both health risks associated with incarceration and the costs of correctional administration

The association between seeing retail displays of tobacco and tobacco smoking and purchase: findings from a diary style survey

ABSTRACT Aims:  To assess the impact of retail displays of tobacco on tobacco smoking and purchase by smokers and attempting quitters. Design:  Population based diary style survey Setting:  NSW, Australia Participants:  998 smokers and 111 attempting quitters. Measurements:  Demographic measures and four-hourly records over four days: number of cigarettes smoked and bought; exposure to cigarette smoking by friends/family or other smokers, and exposure to retail displays of tobacco

Mortality of those who attended drug services in Scotland 1996–2006: Record-linkage study

Abstract: Background: We examine major causes of death amongst persons in contact with drug-treatment services across Scotland during April 1996–March 2006, hereafter Scottish Drug Misuse Database (SDMD) cohort.Methods: Drug-treatment records were linked to national registers of deaths and hepatitis C virus (HCV) diagnoses. For eras 1996/97–2000/01 and 2001/02–2005/06, we calculated cause-specific death-rates and standardised mortality ratios (SMRs) using age-, sex- and calendar-rates of the general Scottish population. Major causes of death were identified by high SMRs (> 5 across eras) or rates (> 50 per 100,000 person-years in either era), and their time-specific influences characterised by proportional hazards analyses.Results: The SDMD cohort comprised 69,456 individuals, 350,315 person-years and 2590 deaths.

CIGX: A Hot Tobacco Stock Ignited by Wild Pipe Dreams?

* Editor’s Note: This story is the first in a two-part investigative series, with the second article scheduled to run after the Fourth of July holiday. Over the years, regulatory filings show, Star Scientific (Nasdaq: CIGX) has often changed its pretty story — with the former cigarette maker now spinning tobacco as the key to breakthrough medical cures – but the company has rarely changed its ugly numbers.